Rexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Patent Covering the Manufacturing of RX-3117 – A Cancer Cell Specific Anticancer Agent Oct 31, 2016
Rexahn Pharmaceuticals Receives U.S. Patent for RX-21101: A Novel Nano-Polymer Conjugate of Docetaxel for the Targeted Treatment of Solid Tumors Oct 26, 2016
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress Oct 10, 2016
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress Oct 4, 2016
Rexahn Pharmaceuticals Initiates stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer Sep 12, 2016
Rexahn Pharmaceuticals to Present at 18th Annual Rodman & Renshaw Global Investment Conference on September 12, 2016 Sep 7, 2016
Rexahn Pharmaceuticals Presents Clinical Data for Three Novel Targeted Oncology Programs at the 2016 American Society of Clinical Oncology Annual Meeting Jun 6, 2016